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1. Introduction 
Cancer is a major public health problem since it is the second leading cause of illness-related 
death, only exceeded by heart disease (American Cancer Society [ACS], (2010)). Cancer 
results from structural and quantitative alterations in molecules that control different 
aspects of cell behavior. Genetic alterations probably represent the most common 
mechanisms for molecular changes that cause the development and progression of cancer 
(Dong, 2006). Great efforts have been made to identify common genetic modifications and 
the underlying target genes. Genetic alterations can be inherited, as in hereditary cancers, or 
induced by endogenous and exogenous carcinogenic factors as in most sporadic cancers 
(Dong, 2006). The six essential changes in cell physiology suggested to collectively dictate 
malignant growth are self-sufficiency in growth signals, insensitivity to anti-growth signals, 
tissue invasion and metastasis, limitless replicative potential, sustained angiogenesis and 
evading apoptosis (Hanahan & Weinberg, 2000). 
Chemotherapeutic agents used in current clinical practice have played a significant role in 
reducing mortality/morbidity and in increasing patient’s quality of life (Suggit & Bibby, 
2005). Despite the recent advances in early diagnosis and in clinical protocols for cancer 
treatment, the development of antineoplastic agents that combine efficacy, safety and 
convenience for the patient remains a great challenge (Ismael et al., 2008).  
Most anticancer drugs have narrow therapeutic index, develop multidrug resistance (MDR) 
and present unspecific biodistribution upon intravenous administration leading to 
unacceptable side effects to healthy tissues, mainly bone marrow and gastrointestinal tract. 
These limitations of conventional chemotherapeutic strategies frequently result in 
suboptimal dosing, treatment delay or discontinuance and reduced patient compliance to 
therapy (Ismael et al., 2008). 
2. Combination chemotherapy 
2.1 Principles and advantages 
Combination therapy has been the standard of care, especially in cancer treatment, since it is 
a rationale strategy to increase response and tolerability and to decrease resistance. 
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Currently, there is a growing interest in combining anticancer drugs aiming at maximizing 
efficacy while minimizing systemic toxicity through the delivery of lower drug doses 
(Mayer & Janoff, 2007; Ramsey et al., 2005; Zoli et al., 2001). 
The fundamentals of combination chemotherapy development have remained largely 
unchanged over the last decades. The general principles have been to: i) use drugs with non-
overlapping toxicities so that each drug can be administered at near-maximal dose; ii) 
combine agents with different mechanisms of action and minimal cross-resistance in order 
to inhibit the emergence of broad spectrum drug resistance; iii) preferentially use drugs with 
proven activity as single drugs and iv) administer the combination at early stage disease and 
at a schedule with a minimal treatment-free period between cycles but still allowing the 
recovery of sensitive target tissues (Mayer & Janoff, 2007; Harasym et al, 2007; Ramsey et al., 
2005; Zoli et al., 2001). The advantages attributed to combination chemotherapy include 
improved patient compliance due to the reduced number of administrations, emergence of 
additive or synergistic interaction effects, ability to overcome or delay MDR and reduction 
of drug dose with consequent diminishing of toxicity to healthy tissues (Chou, 2010, 2006; 
Ramsey et al., 2005).  
As an example, multimodal combination treatments for hormone refractory prostate cancer 
(HRPC) have gained support in the clinical setting over the last decade (De la Taille et al., 
2001). Given the complexity, heterogeneity, resistance and recurrence features of prostate 
cancer, rationally-designed drug combinations are necessary to achieve significant 
therapeutic progress (Armstrong & Carducci, 2006). 
2.2 Preclinical vs. clinical drug combination studies 
The majority of clinical protocols for cancer combination therapies are mainly obtained 
empirically, in the absence of supporting experimental data, or based on results derived 
from retrospective analysis of clinical trials (Zoli et al, 2001; Goldie, 2001). These studies 
investigate the sequencing and scheduling of drugs rather than determining the optimal 
drug interactions. Information obtained from clinical protocols is valuable, but is time-
consuming, expensive and does not provide data on the biochemical and molecular 
mechanisms of drug interaction at cellular level resulted from combined treatments (Zoli et 
al., 2001). It is very difficult to determine whether drug combinations are acting in a 
synergistic, additive or antagonistic fashion in cancer patients. Ultimately, one can only 
determine whether a new combination provides a statistically significant increase in a 
specific end point such as response rate, time to progression or survival (Mayer, 2007). 
Preclinical drug interaction studies allow a more rational design of clinical combination 
chemotherapy protocols, which are generally based on the empiric assumption that 
maximal efficacy will be achieved by co-administering each drug at their maximum 
tolerated doses (MTDs) (Mayer & Janoff, 2007; Harasym et al., 2007; Mayer et al., 2006). This 
“more-is-better” philosophy applied to anticancer combinations may result in higher 
toxicity with minimal therapeutic benefit due to concentration-dependent drug interactions 
(Mayer et al, 2006; Ramsey et al., 2005). Undoubtedly, there are several molecular and 
pharmacological factors that determine the effectiveness of drug combinations. A rationally-
designed fixed drug combination is required since certain drug ratios can be synergistic, 
while others are additive or even antagonistic (Mayer & Janoff, 2007; Mayer et al., 2006). 
The design of preclinical drug combination studies on established cell lines, primary cell 
cultures or animal models has to take into account several factors such as drug 
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concentration, exposure time, drug administration schedule and analytic method for 
evaluating the drug interaction (Zoli et al., 2001). 
2.3 In vitro vs. in vivo drug combination studies  
Evaluation of drug ratio-dependent effects in combination chemotherapy is frequently 
conducted in cell culture systems. During the course of the experiment, concentration and 
duration of administered drug(s) can be tightly controlled and the inhibition of tumor cell 
growth can be easily measured (Mayer & Janoff, 2007; Harasym et al., 2007; Chou et al., 
2006). For the last two decades, in vitro experimentation with tumor-derived cell lines has 
been the most important resource for investigating molecular mechanisms of cancer 
pathogenesis (Mitchell et al., 2000). There are a number of advantages associated with the 
use of cell culture systems, e.g. availability of a wide range of human tumor cell lines, 
flexibility of culture conditions and easiness of protein/nucleic acid quantification 
(Harasym et al., 2007). Additionally, in vitro tests not only evaluate antiproliferative effects 
of tested drugs but also assess interference on cell cycle, induction of apoptosis and 
existence of molecular or biochemical interactions (Zoli et al., 2001). 
Unfortunately, cell culture studies are of limited usefulness because the conditions are 
artificial, do not reflect the heterogeneity of clinical malignant disease and, hence, are unable 
to evaluate the therapeutic index (Budman et al., 2002). Unlike in vitro studies where drug 
concentration is relatively constant, in vivo models represents a dynamic system, where 
drug molecules undergo absorption, distribution, metabolism and elimination, thus leading 
to plasma drug concentration changes over time (Merlin, 1994). Nevertheless, when 
compared to in vitro studies, the determination of synergism or antagonism in vivo using 
animal models is more time consuming, more expensive and greater variability in 
measurements occurs. Therefore, in vivo drug combination studies are usually carried out, 
only for selected drugs, after in vitro evaluation and before clinical trials (Chou, 2010, 2006). 
3. Drug interaction effects in combination chemotherapy  
3.1 Definition and in vitro quantitative evaluation  
A drug combination can result in synergistic, antagonistic or additive interaction effects at 
different concentration ratios. Synergy, additivity and antagonism are defined as the 
interaction between two or more components such that the combined effect is superior, 
equal or inferior, respectively, to the expected sum of individual effects. Additivity means 
that each constituent contributes to the effect in accordance with its own potency (Chou, 
2006; Merlin, 1994). 
Systematic screening analysis of drug combinations can identify additive or synergistic 
relationships previously unrecognized (Mayer & Janoff, 2007). In vitro synergistic activity is 
strongly dependent on drug:drug ratio and that dependence has profound implications on 
clinical application, since in vivo activity relies on the maintenance of those therapeutic 
ratios at the disease site (Mayer & Janoff, 2007; Harasym et al., 2007; Mayer et al., 2006). 
Therefore, in order to achieve maximal therapeutic efficacy in vivo, dosing schedule is 
essential to allow exposure of tumor cells to defined drug concentrations (Zhao et al., 2008). 
Several methods for the quantitative evaluation of drug-combined interaction effects have 
been used and were comparatively reviewed elsewhere (Zoli et al., 2001; Merlin, 1994). A 
brief description of the principles and limitations of the different methods is compiled in 
Table 1. However, in the present book chapter only the median effect analysis is extensively 
reviewed in the next section. 
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Method 
 
 
Author 
 
Principle 
 
Limitations 
Fractional 
product 
Webb  
(1963) 
Summation of the effects of 
two inhibitors is expressed by 
the product of the fractional 
activities 
 
Method does not take into account the 
possible sigmoidicity of the dose 
response curves (m > 1 or m < 1) and is 
not applicable in the case of two 
mutually exclusive drugs or second-order 
mutually non-exclusive drugs 
 
Classical 
isobologram 
Loewe 
(1957) 
Lines join doses or dose-
combinations exerting the 
same effect (iso-effect) 
Method requires a large number of data 
points, has poor computer software, the 
statistical approach is incomplete and 
only two-drug combinations can be 
evaluated. Method is not applicable in 
the case of two mutually non-exclusive 
drugs 
Isobologram 
modified 
Stell and 
Peckham 
(1979) 
Envelope of additivity: a 
region delimited by 
confidence limits in which the 
cytotoxic agents are not 
significantly interacting 
 
Median effect 
analysis 
 
 
Chou and 
Talalay 
(1984) 
 
Enzyme kinetic system: mass 
action law, Michaelis–Menten 
and Hill equations 
 
Method should not be applied when the 
dose–response curves are not sigmoidal 
because of the difficulty of applying 
linear regression analysis 
 
Three-
dimensional 
Fraser (1972) 
Carter and 
Wampler (1986) 
Kanzawa (1997) 
Michaelis–Menten equations 
Median effect principle 
 
Model requires several mathematical 
functions and software for each different 
type of response surface. The complex 
execution prevents it from being widely 
used in preclinical studies  
  
Table 1. Methods for the quantitative evaluation of drug combination effects. Data was 
adapted and compiled from several literature references (Chou, 2006, 1994; Chou & Talalay, 
1984; Zoli et al., 2001; Merlin, 1994). 
3.2 The median effect analysis 
By far the most prevalent method used for quantitative evaluation of drug combinations is 
the median effect analysis proposed by Chou and Talalay (Chou, 2010, 2006, 1994; Chou & 
Talalay, 1984). The fundamental equations of this method were derived from mass action 
enzyme kinetic models, previously established for enzyme-substrate interactions and then 
extended to multiple drug combinations (Chou, 1976). The equations underlying the median 
effect principle can be considered as a generalized form including the concepts of fractional 
product and isobologram analysis (Table 1) (Merlin, 1994; Chou & Talalay, 1984). 
Regardless of the shape of the dose-effect curve or the drug mechanism of action, the 
median effect equation correlates drug dose and corresponding effect (cell growth 
inhibition) and is given by: 
 fa / fu = (D/Dm) m                                     (1) 
Where fa and fu are the fractions of cells affected and unaffected, respectively, by a dose (D); 
Dm is the dose causing the median effect and m the coefficient traducing the shape of the 
dose effect curve (m = 1, >1 and < 1, indicate hyperbolic, sigmoidal and negative sigmoidal, 
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respectively). The m and Dm parameters are easily determined from the median effect plot 
since they correspond to the slope and to the antilog of the x-intercept, respectively (Chou 
2006, 1994; Chou et al. 1994). When m and Dm are determined, the entire dose-effect 
relationship is described since for a given dose (D) it is possible to calculate the effect (fa) 
and vice-versa (Chou, 2010, 1994). Application of equation 1 allows the linearization of 
hyperbolic (m = 1) as well as sigmoidal curves (m ≠ 1) which are often encountered in 
chemotherapy treatment data (Merlin, 1994; Chou & Talalay, 1984). Plotting x = log(D) vs. y 
= log(fa/fu) based on the logarithm form of equation 1 is called the median effect plot (Chou, 
2010, 2006) (Fig. 1).  
 
 
Fig. 1. Graphical representations executed in the median effect analysis method. Three 
sigmoidal dose-effect curves (a, b, c) (left graph) and respective transformation into the 
corresponding linear forms by the median effect plot (right graph), where y = log(fa/fu) vs. 
x = log(D). Adapted from reference (Chou, 2006). 
The conformity of the data to the median effect principle can be readily manifested by the 
linear correlation coefficient (r) of the plot, in which r = 1 indicates perfect conformity 
(Chou, 2010, 2006, 1994). The fractional effect associated with a range of concentrations is 
determined for each individual drug and for their combination. The median effect plot gives 
parallel lines if the drugs have the same or similar modes of action and the effects are then 
considered mutually exclusive; if the plots for single drugs are parallel but the mixture plot 
is concave upward with the tendency to intersect the plot of the more potent drug, the drugs 
act independently and their effects are considered mutually non-exclusive (Chou & Talalay, 
1984). 
The combination index (CI) quantitatively evaluates the nature of drug interaction and is 
defined by the following equation: 
 CI = 
1
1
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                 (2) 
Where α = 0 and  α = 1, for drugs with mutually exclusive or non-exclusive mechanisms of 
action, respectively (Chou, 2010, 2006, 1994; Chou & Talalay, 1984). Denominators (Dx)1 and 
(Dx)2 are drug doses required to achieve a given effect level (fa). Numerators (D)1 and (D)2 
are doses of each drug in a given mixture which originates the same fa. For three-drug 
combinations, a third term (D)3/(Dx)3 is added to equation 2. A plot of CI as a function of 
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effect level (fa) is represented in Fig. 2. CI values reflect synergism, additivity or antagonism 
when inferior, equal or superior to 1, respectively. 
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Fig. 2. Graphical representation of an exemplificative CI - fa plot. Combination index (CI) < 
1, = 1, > 1 indicate synergism, additivity and antagonism, respectively. 
If the nature of drug mechanisms is not clear, the authors of the method suggest that CI 
value must be determined by both mutually exclusive (α = 0) and mutually non-exclusive (α 
= 1) assumptions. The later approach is more conservative as the addition of a third term in 
equation 2 results in higher CI values than the former one (Chou, 2006, 1994, Chou & 
Talalay, 1984). Even though the CI value can be expressed for any effect level, the most 
accurate determination is for fa = 0.5 since the median effect plot may be unreliable at the 
extremes as it represents a linear approximation of a non-linear function (Kreis et al., 2001). 
The median effect analysis is a simple quantitative method that takes into account not only 
the potency (Dm) of each drug and of their combination but also the shape (hyperbolic or 
sigmoidal) of their dose-effect curves (Chou, 1994; Chou et al., 1994). Furthermore, this 
method evaluates interaction effects at different drug ratios, at different effect levels and up 
to three agents can be evaluated simultaneously (Chou et al., 1994; Chou & Talalay, 1984). It 
is recommended that an experiment should be carried out using a constant equipotency 
ratio (e.g. (IC50)1/(IC50)2) so that the effect contribution of each drug to the combination can 
be roughly equal (Chou, 2010, 2006; Chou & Talalay, 1984). When evaluating anticancer 
drug combinations, the dose range administered must be wide enough to allow 
extrapolation of the results up to high levels of activity, i.e. fa ≥ 0.5, owing to the fact that 
tumor growth inhibition below that level is not clinically meaningful (Chou, 2010; Harasym 
et al., 2007; Merlin, 1994). 
Dose reduction index (DRI) is a measure of how many folds the dose of a combined drug 
may be reduced at a given effect level as compared to the dose of the drug alone (Chou, 
2006; Mayer et al., 2006). DRI is an important parameter in clinical practice because a 
favorable value (> 1) may lead to reduced systemic toxicity toward healthy tissues while 
maintaining therapeutic efficacy (Chou, 2010, 2006, 1998, 1994; Chou & Talalay, 1984). 
4. Nanoparticles as drug delivery systems 
In face of the difficulties and high costs inherent to the development of new therapeutic 
molecules, the strategy of most pharmaceutical companies seems to rely on the optimization 
of the existing drugs, namely those characterized by a low therapeutic index. In particular, 
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the application of nanotechnology-based drug delivery systems, such as liposomes, to 
cancer chemotherapy has been an exciting and promising area of research and constitutes an 
important ongoing effort to improve specificity and efficacy of anticancer drugs. 
4.1 Different types of nanoparticles 
Several drugs have physical and biological properties which hinder their clinical 
applicability, namely poor water solubility, rapid metabolism, instability under 
physiological conditions, unfavorable pharmacokinetics and unspecific biodistribution to 
healthy tissues (Allen, 1998). Particularly, in the case of anticancer drugs, such features 
ultimately lead to inadequate delivery of effective therapeutic drug concentrations to tumor 
tissue and/or unacceptable toxic effects (Andresen et al., 2005; Cattel et al., 2003). Therefore, 
it is crucial to develop nanotechnology-based platforms (lipid or polymer-based 
nanocarriers such as liposomes, micelles, polymeric nanoparticles or dendrimers) to 
promote and control delivery of some anticancer drugs to tumors (Devalapally et al., 2007; 
Peer et al., 2007; Dutta, 2007) (Fig. 3).  
Nanoparticles with medical applications differ in terms of structure, size and composition, 
thus resulting in different characteristics, namely drug loading capacity, physical stability 
and targeted delivery ability (Haley & Frenkel, 2008). It is beyond the scope of this chapter 
to review the current drug delivery nanocarriers since they have been widely reviewed in 
recent publications (Devalapally et al., 2007; Peer et al., 2007; Dutta, 2007; Haley & Frenkel, 
2008; Lammers et al., 2008; Cho et al., 2008; Alexis et al., 2008). Therefore, in this chapter an 
overview will be restricted to liposomes, since these are probably the most used drug 
delivery system for small drug molecules. 
 
 A B C D  
Fig. 3. Schematic representation of exemplificative nanocarriers for drug delivery. A 
Liposome; B Polymeric nanoparticle; C Micelle; D Dendrimer. Adapted from reference 
(Devalapally et al., 2007). 
4.2 Liposomes 
4.2.1 General definition and main features 
Liposomes were firstly described by Bangham et al. (Bangham et al., 1965) and were 
originally called phospholipid spherules. Liposomes are self-assembling closed colloidal 
lipid vesicles (Fig. 4) with considerable potential for delivery of therapeutic agents due to 
several features: biodegradability, biocompatibility, simplicity, scaled-up production, low 
inherent toxicity, weak immunogenicity, versatility in structure and in physicochemical 
properties (lipid composition, size and surface charge) and ability to undergo surface 
engineering towards conjugation of polymers and targeting ligands (Immordino et al., 2006; 
Hofheinz et al., 2005; Cattel et al., 2003). Due to those specific attributes, liposomes have the 
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ability to modulate in vivo behavior (pharmacokinetics and biodistribution profile) and/or 
solubility properties of drugs and to protect them from premature degradation or 
inactivation after intravenous administration (Fenske et al., 2008; Immordino et al., 2006; 
Drummond et al., 1999; Allen, 1998). In general, when a drug is encapsulated within a 
carrier, such as liposome (Fig. 4) the plasma clearance and volume of distribution decrease 
while the plasma circulation half-life (t1/2) and area under the plasma concentration vs. time 
curve (AUC) increase (Gabizon et al., 2003). 
 
 
Fig. 4. Schematic representation of a liposome vehicle with drug molecules encapsulated in 
the aqueous internal compartment. 
The pharmacokinetics, biodistribution and biological activity of a liposomal drug 
formulation are influenced by size, surface charge, lipid and drug doses, lipid composition, 
steric stabilization and route of administration (Charrois & Allen, 2004, 2003; Nagayasu et 
al., 1999; Mayer et al., 1989). 
The development of a successful therapeutic liposomal drug formulation must comply with 
three fundamental requisites: i) clear knowledge of the biology and physiology of the 
disease to be treated; ii) good understanding of the physicochemical properties of both the 
carrier and the drug and iii) determination of the pharmacokinetic and biodistribution 
changes induced in the drug by the liposomal vehicle (Allen, 1998). 
Liposome structural types, physicochemical composition and preparation methods will not 
be overviewed in the present chapter since they have been thoroughly reviewed over the 
last two decades, in particular by Dr. Allen (Allen, 1998, 1997, 1994) and Dr. Lasic (Lasic et 
al., 1999) research groups. 
4.2.2 Medical applications 
In the past decades there have been major advances in the development of liposomal drug 
formulations suitable for several medical applications. In addition to their feature as drug 
delivery systems in the treatment of cancer, bacterial infections or ophthalmic disorders, 
current clinical applications of liposomes also include gene delivery, diagnostic imaging, 
vaccine adjuvant, photodynamic therapy, dermatology, hemoglobin or chelating agent 
transporter and enzyme replacement therapy (Fenske et al., 2008; Torchillin, 2007; 
Immordino et al., 2006; Torchillin, 2005; Gregoriadis & Florence, 1993). The ultimate goal of 
an anticancer liposomal formulation is to improve overall therapeutic index of encapsulated 
drugs by increasing the antitumor activity and/or by reducing the toxicity profile, due to 
preferential delivery and accumulation at tumor tissue as compared to free drugs 
(Drummond et al., 1999; Gabizon, 1992). 
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4.2.3 In vivo behavior: From conventional to sterically stabilized liposomes 
Ideally, liposomal drug formulations should have a mean diameter centered on 100 nm, a 
high drug-to-lipid ratio, an excellent retention of encapsulated drug(s) (while circulating in 
the blood) and a long circulation lifetime (from hours to days) (Fenske & Cullis, 2005). In 
general, the short blood residence time and in vivo drug leakage profile of conventional 
liposomes hinder their clinical applicability. Liposomes are recognized and bounded by 
serum proteins (opsonins) (Fig. 4) and by complement system after which they are cleared 
from systemic circulation by reticulo-endothelial system (RES) cells of the liver, spleen and 
bone marrow (Immordino et al., 2006; Chonn et al., 1992; Papadjopolous et al., 1991). The 
physicochemical properties of liposomes, such as net surface charge, hydrophobicity, size, 
fluidity and packing of the lipid bilayer, influence their stability and the type of proteins 
that bind to them (Chonn et al., 1992). Moreover, lipid exchange with plasma lipoproteins 
can destabilize liposomes and lead to their rupture with release of entrapped content 
(Immordino et al., 2006). The use of saturated phospholipids with high phase transition 
temperature associated with cholesterol, but mostly surface coating with a synthetic 
hydrophilic polymer such as poly(ethylene glycol) – PEG (Fig. 4) or with ganglioside GM1, 
significantly extend bloodstream circulation time to several days and reduces RES clearance 
(Immordino et al., 2006; Gabizon et al., 2003; Allen, 1994, Papahadjopoulos et al., 1991; 
Gabizon & Papahadjopoulos, 1988). Nevertheless, there are some disadvantages associated 
with PEG coating. There is some evidence that pegylated liposomes are not completely inert 
and can still induce activation of complement system (Immordino et al., 2006). Furthermore, 
the presence of PEG may hinder drug release to the target cell population (Harrington et al., 
2002). Attempts have been made to solve these limitations by generating liposomes that are 
reversibly pegylated as described in detail elsewhere (Immordino et al., 2006; Harrington et 
al., 2002). 
Pegylated liposomes are named sterically stabilized liposomes (SSL) or Stealth® due to a 
highly hydrated surface, constituted by the hydrophilic PEG and water molecules, that acts 
as a steric barrier and prevents protein adsorption and opsonization (Fig. 5)  (Immordino et 
al., 2006; Andresen et al., 2005; Gabizon et al., 2003). 
 
 
Fig. 5. Graphical representation of PEG-coated liposome (Stealth®). Extent of opsonization of 
pegylated liposomes is significantly diminished due to their highly hydrated surface. 
Adapted from reference (Allen, 1997). 
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4.2.4 The enhanced permeability and retention effect in tumor tissues 
Most solid tumors possess unique pathophysiological characteristics that are absent in 
normal tissues, such as extensive and unregulated angiogenesis, defective vascular 
architecture, enhanced vascular permeability, dysfunctional lymphatic drainage and 
increased production of a number of permeability mediators (Gabizon et al., 2006; Maeda et 
al., 2000). This enhanced permeability and retention effect (EPR) inherent to solid tumors 
(Fig. 6) (Maeda et al., 2000; Drummond et al., 1999) has been described in several 
experimental tumors and depends mainly on tumor volume, vascularization and leakage 
from blood vessels (Gabizon et al., 2006; Yuan et al., 1995). Long-circulating liposomal drug 
formulations with size diameter within the range of 100-150 nm demonstrate preferential 
extravasation through leaky tumor vasculature and passively accumulate in the interstitial 
space due to the EPR effect. The release of drug molecules from liposomes into the tumor 
interstitium provides locally drug delivery at therapeutic dose levels (Abraham et al., 2005; 
Drummond et al., 1999; Gabizon & Papahadjopoulos, 1988). Interestingly, a particular study 
on tumor xenograft animal models reported that liposomes up to 400 nm can extravasate 
across tumor vessels and penetrate into tumor interstitium, suggesting that the threshold 
vesicle size of the pores is generally between 400 and 600 nm in diameter (Yuan et al., 1995). 
Nevertheless it is important to emphasize that the cut-off range mostly depends on tumor 
type. The extent of accumulation within the tumor is largely determined by the circulation 
lifetime of the liposomes (Song et al., 2006). Moreover, the impaired lymphatic drainage in 
the tumor interstitium favors the retention of liposomal formulations at the extravasation 
site, accentuating the passive targeting to solid tumors (Fig. 5) (Gabizon et al., 2006; Maeda 
et al., 2000; Drummond et al., 1999). 
 
 
Fig. 6. Enhanced permeability and retention effect (EPR). Liposomes are shown as 
representative nanoparticles. Tumor targeting is achieved by passive extravasation of 
liposomes, from blood to tumor interstitium through highly permeable vasculature, and by 
accumulation in interstitial space due to non-functional lymphatic system in solid tumors. 
Adapted from reference (Peer et al., 2007). 
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4.2.5 Liposomal single drug formulations approved for clinical use or under clinical 
evaluation 
The success of liposomes as drug delivery systems has been reflected by the significant 
number of formulations which are FDA or EMA-approved for clinical use (Table 2) or 
undergoing clinical evaluation (Table 3). 
Representative examples of liposomal single drug formulations that have gained regulatory 
approval for clinical use are Doxil® and Myocet®. These LUV formulations encapsulating 
doxorubicin are being marketed for the treatment of several cancers, either as an individual 
formulation or in combination treatments (Table 2). Liposomal anthracyclines, namely 
doxorubicin, have raised significant interest due to their ability to decrease drug-related 
toxicity (cardiomyopathy, which can lead to congestive heart failure and death, bone 
marrow suppression, alopecia or nausea) with no associated loss of therapeutic activity 
(Abraham et al., 2005; Gabizon et al., 2003, 1998). 
 
 
Formulation 
brand name 
 
 
Drug name 
 
 
 
Dosage form 
/ route 
 
 
Therapeutic indication
 
 
Date 
 
 
Company 
name 
 
Abelcet
®
 
Amphotericin B 
Lipid complex 
/injection 
Systemic fungal infection 1995 Enzon 
AmBisome
®
 
Liposomal/ 
injection 
Systemic fungal infection 1997 Astellas Pharma 
Amphotec
®
 
Lipid complex 
/injection 
Systemic fungal infection 1996 
Three Rivers 
Pharms 
DaunoXome
®
 
Daunorubicin 
citrate 
Liposomal/ 
injection 
AIDS-related Kaposi’s 
sarcoma  
Breast cancer and other 
solid tumors 
1996 Diatos S.A. 
DepoCyt
®
 Cytarabine 
Liposomal/ 
injection 
Lymphomatous meningitis 
(intrathecal application) 
1999 
Pacira 
Pharmaceuticals 
Inc. 
DepoDur
®
 Morphine sulfate 
Liposomal/ 
epidural 
Post-surgical pain reliever 2004 
Pacira 
Pharmaceuticals 
Inc. 
Doxil
®
(USA) 
Doxorubicin.HCl 
Liposomal/ 
injection 
AIDS-related Kaposi’s 
sarcoma 
Advanced ovarian cancer 
Metastatic breast cancer 
Multiple myeloma 
(combination with 
bortezomib) 
1995 
Centocor Ortho 
Biotech Inc. 
Caelyx
® 
(Europe) 
1996 
Schering Plough 
Europe 
Myocet
®
 Doxorubicin.HCl 
Liposomal/ 
injection 
Metastatic breast cancer 
(in combination with 
cyclophosphamide) 
2000 
Cephalon 
Europe 
Visudyne
®
 Verteporfin 
Liposomal/ 
injection 
Age-related macular 
degeneration 
2000 
QLT Inc. 
/Novartis 
  
Table 2. Current FDA or EMA-approved liposomal single drug formulations for different 
clinical applications. Source: official website of USA Food and Drug Administration (FDA) - 
http://www.fda.gov (2010) and European Medicines Agency (EMA) - 
http://www.ema.europa.eu (2010).  
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Formulation 
brand name 
 
 
Therapeutic 
agent 
 
Therapeutic indication 
 
 
Company name 
 
 
Status 
 
Annamycin 
Acute lymphocytic leukemia 
Acute myelogenous leukemia 
Breast cancer 
Callisto 
Pharmaceuticals 
New York University 
School of Medicine 
Phase I/II 
 
Phase I/II 
Aroplatin 
Platinum 
agent NDDP 
Colorectal cancer 
Aronex 
Pharmaceuticals 
Phase II 
Atragen Tretinoin 
Hodgkin’s lymphoma 
 
Metastatic kidney cancer 
M.D. Anderson 
Cancer Center 
Weill Medical 
College of Cornell 
University 
Phase II 
 
 
Phase II 
Cisplatin Lung cancer Transave Phase II 
LE-SN28 
Irinotecan 
metabolite 
SN38 
Advanced cancer NeoPharm Phase I 
LEP-ETU Paclitaxel Advanced cancer NeoPharm Phase I 
Marqibo® Vincristine 
Acute lymphoblastic leukemia  
Malignant melanoma 
Hana Biosciences 
Phase II 
Phase I/II 
Mitoxantrone Advanced cancer NeoPharm Phase I 
Nystatin 
Systemic fungal infection 
in patients with hematologic 
cancer 
Aronex 
Pharmaceuticals 
Phase III 
OSI-211 Lurtotecan 
Ovarian cancer 
Small cell lung carcinoma 
OSI Pharmaceuticals Phase II 
SPI-77 Cisplatin Ovarian cancer 
New York University 
School of Medicine 
Phase II 
Stimuvax® 
BLP25 
vaccine 
Non-small cell lung cancer 
EMD Serono and 
Oncothyreon 
Phase III 
Topotecan 
Small cell lung cancer 
Ovarian cancer 
Other solid tumors 
Hana Biosciences, Inc Phase I 
Vinorelbine 
Advanced solid tumors 
Non-Hodgkin's lymphoma 
Hodgkin's lymphoma 
Hana Biosciences, Inc Phase I 
  
Table 3. Examples of emerging liposomal single drug formulations currently undergoing 
clinical evaluation for cancer treatment. Currently, some liposomal drugs have no brand 
name and, therefore, are identified by the drug name. Data was compiled from 
http://www.phrma.org (2009) and from literature references (Lammers et al., 2008; Dutta, 
2007; Torchillin, 2007, 2005; Immordino et al., 2006; Hofheinz et al., 2005) with actualization 
of current clinical status after consult of http://clinicaltrials.gov/ (2010). 
Currently, there are no approved liposomal drugs for treatment of urologic cancers. 
Nevertheless, some liposomal drug formulations listed in Table 4 are under clinical 
evaluation for prostate cancer treatment. 
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Formulation name 
 
 
Treatment 
 
 
Therapeutic 
indication 
 
 
Company name 
 
 
Status 
 
Pegylated liposomal 
doxorubicin 
hydrochloride 
Monotherapy 
Prostate cancer 
(associated with 
hyperthermia 
treatment)
Celsion Phase I 
 
Monotherapy 
 
Hormone-
refractory 
prostate cancer 
(HRPC) 
 
 
Ireland Cancer Center 
 
 
Phase II 
 
Doxil
®
 
In combination 
with 
estramustine 
Ortho Biotech, Inc. Phase I/II 
Doxil
®
 
In combination 
with thalidomide 
Ortho Biotech, Inc. Phase II 
Doxil
®
 
In combination 
with Taxotere
®
 
James Graham Brown 
Cancer Center 
Phase I/II 
 
Table 4. Liposomal single drug formulations currently under clinical evaluation for prostate 
cancer treatment. Data was compiled after consult of http://clinicaltrials.gov/ (2010). 
4.2.6 Liposomal formulations of anticancer drug combinations 
4.2.6.1 General considerations 
The use of drug combinations has been standard of care for the treatment of cancer over the 
last decades. Nevertheless, the application of liposomes as carriers for anticancer drug 
combinations has been described in literature only in the last few years (Tardi et al., 2009; 
Harasym et al., 2007; Tardi et al., 2007; Mayer et al, 2006). To our knowledge, there are no 
liposomal drug combinations approved for clinical application. As previously mentioned in 
section 3.1 drug combinations can act synergistically, additively or antagonistically depending 
on the ratio of the agents being combined (Chou, 2006). While this relationship can be readily 
evaluated in vitro, where drug ratios can be controlled, the translation of those ratios to the 
clinical setting is complex due to the independent pharmacokinetics, biodistribution and/or 
metabolism of the individual drugs intravenously administered as aqueous-based free drug 
cocktail (Mayer et al., 2006; Lee, 2006). Therefore, the referred uncoordinated pharmacokinetics 
results in exposure of tumor cells to drug concentrations below therapeutic threshold level or 
to antagonistic drug ratios with concomitant loss of therapeutic activity (Mayer & Janoff, 2007; 
Harasym et al, 2007). The inability to control drug ratios in systemic circulation, and mainly in 
tumor tissue, may partly explain the short outcome in clinical efficacy seen for conventional 
free drug combinations (Mayer & Janoff, 2007).  
Drug delivery systems, such as liposomes, can control the release of drug combinations such 
that fixed drug ratios are maintained after systemic administration. This tight control 
provides significant improvements in efficacy as compared to free drug cocktail and to 
individual liposomal drugs (Tardi et al., 2009, Mayer & Janoff, 2007; Harasym et al., 2007; 
Mayer et al., 2006; Lee, 2006). In 2006, Mayer and colleagues were the first to investigate the 
importance of maintaining an optimal drug combination ratio in vivo through drug 
encapsulation in liposomes (Mayer et al., 2006). Further studies (Tardi et al., 2009; Harasym 
et al., 2007) have demonstrated that in vitro drug interaction effects can be translated in vivo 
since liposomes can synchronize pharmacokinetics and biodistribution of drug 
combinations and deliver them to tumor tissue at a specific drug ratio (Fig.7, lower panel). 
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This “ratiometric” dosing approach has the potential to be applied to other diseases besides 
cancer in which multiple interacting mechanisms are responsible for disease progression or 
response to therapeutic interventions (Mayer & Janoff, 2007). In contrast, the combination 
injected as a free drug cocktail rapidly distributes into healthy and tumor tissues at drug 
ratios that differ from the administered one (Fig.7, upper panel). 
 
 
 
Fig. 7. Description of how clinical application of drug–drug synergy depends on controlled 
delivery of the desired drug ratio to the in vivo target. Upper panel - a drug cocktail is 
prepared at the desired ratio but biodistribution, metabolism and excretion processes will 
act differentially on the two drugs and cause the ratio to vary after intravenous injection. 
The two drugs distribute extensively into tissues shortly after injection and the ratio that 
reaches the tumor has been displaced 5-fold from the initially injected 1:1 ratio. Lower panel 
- liposomes that contain the synergistic 1:1 ratio maintain and selectively deliver this drug 
ratio to the tumor. The appropriately designed drug delivery vehicle maintains the drugs in 
the blood at higher concentrations for extended periods of time and, most importantly, at 
the effective synergistic ratio. Reproduced from reference (Mayer & Janoff, 2007). 
Therefore, it can be concluded that liposome nanotechnology constitutes a valuable tool for 
preclinical assessment of drug combinations for clinical development (Lee, 2006). 
Advantages of liposomal drug combination delivery are summarized in Table 5. 
Celator Pharmaceuticals were pioneers in liposomal drug combination design and have 
some products under clinical development and preclinical programs, which are 
summarized in Table 6. Currently, CPX-351 and CPX-1 are the only liposomal drug 
combinations under testing in clinical trials (http://clinicaltrials.gov (2010)) but none of 
them is intended for prostate cancer therapy. 
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1. Injection of multiple drugs simultaneously 
2. Identical pharmacokinetic profile for multiple drugs reflecting the profile of the lipid carrier 
3. Tight control of drug concentration at the target sites by changing the drug combined ratio in the 
liposome 
4. Maximal combination effects can be achieved by synergistic action of multiple drugs after 
cellular uptake 
5. Versatile design of the loading methods and membrane lipid composition to control drug release 
6. Improvement of patient compliance and quality of life due to reduced number of injections and 
of side effects while increasing efficacy  
Table 5. Advantages of liposomal drug combination delivery. Adapted from reference (Bae 
et al., 2007) 
 
 
Product name 
 
 
Liposomal drug combination 
 
 
Therapeutic indication 
 
 
Status 
 
CPX-351 Cytarabine : daunorubicin Acute myeloid leukemia Phase II 
CPX-1 Irinotecan HCI : floxuridine Colorectal neoplasms Phase II 
CPX-571 Irinotecan HCl : cisplatin Small cell lung cancer Preclinical 
CPX-8XY Unknown Unknown Research 
 
Table 6. Liposomal drug combinations developed by Celator Pharmaceuticals. Source: 
Celator Pharmaceuticals (http://www.celatorpharma.com (2010)). 
4.2.6.2 Design of liposomal formulations for drug combination delivery 
The concept of combining drugs, with dissimilar physicochemical properties, into a single 
vehicle, that efficiently encapsulates both drugs and releases them at the same rate after 
administration in vivo, represents a major scientific and technical challenge. Presently, 
liposomal encapsulation represents a new paradigm for formulating anticancer drug 
combinations. Although this approach has emerged as a promising strategy for cancer 
treatment, there are a limited number of research studies reporting successful drug co-
loading in the same carrier (Tardi et al., 2009; Zhao et al., 2008; Harasym et al., 2007; Mayer 
et al., 2006). This is likely the result of technical difficulties associated with the efficient and 
stable encapsulation of two drugs inside a single carrier as well as challenges in controlling 
the drug leakage rate and still maintaining the entrapped drug:drug ratio after systemic 
administration (Harasym et al., 2007; Tardi et al., 2007). 
There are three different approaches to formulate a drug combination involving liposomal 
design: i) combination of a liposomal drug with a free drug; ii) encapsulation of two drugs 
in individual liposomal carriers that are subsequently combined at the desired ratio and iii) 
co-encapsulation of two drugs in the same carrier by means of a simultaneous or a 
sequential drug loading. The advantages and limitations of each strategy are discussed 
below in more detail and in the mentioned order: 
i. A liposomal drug formulation can be administered together with a free drug but 
unfavorable liposome-free drug interactions may occur, such as hydrophobic 
interactions or loading of the free drug into liposomes exhibiting a pH gradient 
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(Waterhouse et al., 2001; Mayer et al., 1999). Therefore, these interactions may induce 
changes in the pharmacokinetic parameters of the free and encapsulated drugs as well 
as of the lipid carrier, leading to decreased efficacy and/or increased toxicity 
(Waterhouse et al., 2001). 
ii. Perhaps the most straightforward approach to coordinate the pharmacokinetics of a 
drug combination would be to encapsulate each drug independently into different 
liposomes that provide the required drug retention properties and, subsequently, to 
mix the liposomes in a single suspension at the desired drug:drug ratio. Nevertheless, 
this protocol of formulating drugs in individual liposomes and ultimately administrate 
to patients would be extremely expensive due to the high costs inherent to lipid 
constituents and to the manufacturing process of two separate formulations (Harasym 
et al., 2007).  
iii. Co-encapsulation of two drugs in the same liposomal carrier seems to be a preferable 
solution as compared to administration of individual liposomal drugs since it reduces 
cost production, minimizes lipid load to the patient, which has been associated to 
infusion-related side effects, and eliminates the potential interference that each 
liposome population may exert in the pharmacokinetic profile of the other (Harasym et 
al., 2007; Tardi et al., 2007). Furthermore, co-encapsulation overcomes potential 
uncertainties about drug biodistribution provided by the different liposome 
compositions. By encapsulating a drug combination into a single liposome, the two 
agents are no longer metabolized and eliminated independently but rather distributed 
as a unit, dictated by the characteristics of the carrier. However, this approach 
represents a technical challenge in order to develop a liposomal formulation that 
matches drug release kinetics for both drugs. To accomplish such purpose, 
experimental parameters and liposome features, such as drug loading methods and 
lipid composition, must be systematically optimized during formulation development 
(Harasym et al., 2007). 
4.2.6.3 Development of a liposomal drug combination for prostate cancer: an example 
In the last few years our group has performed an extensive and systematic preclinical study 
to evaluate the in vitro biologic activity of traditional and novel anticancer drugs and, 
ultimately, identify new drug combinations with therapeutic potential for the treatment of 
prostate cancer. Combinations were selected among different drugs (ciprofloxacin, 
docetaxel, doxorubicin, etoposide, imatinib, mitoxantrone and vinblastine) representative of 
distinct mechanisms of action. Several treatment schemes were evaluated by varying 
schedule, type of administration (simultaneous or sequential) and drug:drug molar ratio. 
The nature of antiproliferative combined effects (synergism, additivity or antagonism) 
against metastatic prostate cancer cell lines was quantitatively assessed by the median effect 
analysis method, whose main parameters are combination index (CI) and dose reduction 
index (DRI) (Pinto et al. 2011a, 2009). 
Combination of two drugs tested simultaneously, comprising at least one topoisomerase II 
inhibitor, result in mild antagonistic effects against PC-3 and LNCaP cells. This antagonism 
of growth inhibition effects is translated by a CI superior to 1 and by a DRI inferior to 
twofold. In contrast, imatinib-mitoxantrone and ciprofloxacin-etoposide simultaneous 
combinations interact additively in inhibiting PC-3 cell growth, yielding CI values close to 1 
and DRI values of 2.6 and 3.5-fold for mitoxantrone and etoposide, respectively (Pinto et al. 
2011a, 2009).  
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The use of liposomes as drug delivery systems has been exploited in order to improve 
overall therapeutic index of anticancer drugs by increasing their antitumor activity and/or 
by reducing their toxicity profile. The main goal of our studies was to develop and 
characterize a novel liposomal formulation, for simultaneous co-loading and delivery of a 
drug combination previously identified in cytotoxicity screening studies performed in our 
laboratory, and to evaluate its in vitro and in vivo antitumor activity against HRPC 
preclinical models. The rationale for selecting imatinib-mitoxantrone combination was to 
investigate if co-loading of those two drugs into a liposome could translate the additive 
growth inhibition effects exerted on PC-3 cells when these drugs were combined 
simultaneously in the free form. Another selection criterion was that these drugs exhibit 
non-overlapping toxicity profiles and different mechanisms of action, so potential side 
effects and resistance phenomena could be minimized. Moreover, this combination is 
innovative for prostate cancer therapy since it conciliates a conventional antineoplastic drug 
(mitoxantrone), which is standard of care for palliative treatment of HRPC, with a 
molecular-targeted agent (imatinib), which has exhibited antitumor activity against in vitro 
and in vivo HRPC models. 
Systematic development studies, by varying drug loading methods and incubation 
conditions, were carried out in order to design a liposomal imatinib-mitoxantrone (LIM) 
formulation that while being stable would exhibit adequate features for intravenous 
administration. Obtained results provide clear evidence that the two drugs can be 
simultaneously loaded, with high encapsulation efficiency (> 95%), in a single liposomal 
carrier using a transmembrane (NH4)2SO4 gradient-based procedure. According to 
literature, our study was the first to report an active loading method for imatinib (Pinto et al. 
2011b).  
In vitro studies performed on PC-3 cells showed that LIM formulation, at an optimized 
drug:drug molar ratio, exhibits enhanced tumor cell growth inhibition and promotes a 2.6-
fold reduction of IC50 as compared to single liposomal mitoxantrone. This dose reduction is 
equivalent to the one found for mitoxantrone in free drug combination against the same cell 
line (Pinto et al. 2011a). Therefore, the therapeutic gain in mitoxantrone efficacy, mediated 
by imatinib and that result from free drug combination, is also attainable after liposomal 
encapsulation of the drugs at an optimized drug:drug ratio (Pinto et al. 2011b).  
In vivo therapeutic activity of developed liposomal formulations, comprising different doses 
of single or imatinib-combined mitoxantrone, was evaluated in a nude mice bearing 
subcutaneous PC-3 xenograft model. Obtained results clearly demonstrate that intravenous 
administration of the liposomal formulation co-loading a low mitoxantrone dose (0.5 
mg/kg) with imatinib (10 mg/kg) enables a tumor growth inhibition similar to the one 
yielded by single liposomal mitoxantrone (2.0 mg/kg), i.e. with a 4-fold inferior dose. This 
dose reduction could minimize the occurrence of side effects and hence increase therapeutic 
index of mitoxantrone (Pinto et al. 2011b).  
Our results clearly emphasize the potential of incorporating clinically relevant drug 
combinations, at specific therapeutic ratios, within a lipid-based delivery system. Our 
research study is the first to provide a proof-of-principle for imatinib use in improving in 
vitro and in vivo antitumor efficacy of liposomal mitoxantrone. Overall, the developed LIM 
formulation constitutes a novel nanotechnology-based drug combined platform with 
improved therapeutic outcome against HRPC. 
www.intechopen.com
 
Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
710 
5. Conclusion 
The up-to-date approach intended to develop novel chemotherapeutic drug combinations 
should be based on a rational selection of the drugs to be combined and on a systematic and 
quantitative screening of the ratio-dependent antiproliferative effects against human tumor 
cell lines. Drug combination studies on tumor cell lines, using a quantitative method to 
evaluate the nature of drug interactions, allow a more rational design of future 
chemotherapy protocols. 
The translation of specific drug ratios, previously selected in vitro, to the clinical setting is 
complex due to the independent pharmacokinetics and biodistribution of individual drugs 
intravenously administered as aqueous-based free drug cocktail. The referred 
uncoordinated pharmacokinetics results in exposure of tumor cells to drug concentrations 
below therapeutic threshold level or to antagonistic drug ratios with concomitant loss of 
therapeutic activity. The inability to control drug ratios in systemic circulation, and mainly 
in tumor tissue, may partly explain the short outcome in clinical efficacy seen for 
conventional free drug combinations. 
The extensive in vitro information on drug ratios can be used to formulate drug 
combinations in drug delivery systems. The use of liposomes as drug delivery systems has 
been successfully exploited in order to improve overall therapeutic index of anticancer 
drugs by increasing their antitumor activity and/or by reducing their toxicity profile. 
Successful clinical application of this rationally-designed approach to cancer therapy 
depends on the development of a liposomal formulation, with specific features, that delivers 
the drug combination in vivo so that the effective drug ratio is maintained after systemic 
administration and is ultimately exposed to tumors. 
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